Syngenta announces new seed treatment option for soybean farmers
The EPA has registered a new seed treatment innovation from Syngenta. CruiserMaxx APX offers soybean farmers protection against early-season insects and disease.
CruiserMaxx APX combines Syngenta’s CrusierMaxx Vibrance seed treatment with picarbutrazox, a novel mode of action. The seed treatment provides protection against Pythium and Phytophthora, as well as Fusarium, Rhizoctonia, seed-borne diseases, and early-season insects.
“Early-season diseases like Pythium and Phytophthora cause reduced plant stands, root rot, stunting, and limited yield potential,” says Dale Ireland, Syngenta Seedcare technical lead, in a news release. “As U.S. soybean growers continue to plant earlier with reduced seeding rates, early–season Pythium protection is more important now than ever before. Maximizing soybean yield starts with minimizing stand loss, damping-off, and consequent replanting caused by these seedling diseases.”
Formulated with various planting conditions and soybean growing trends in mind, CruiserMaxx APX gives farmers flexibility in how and when they plant.
“No matter if you plant early into cool, wet soils or later into a warmer, double-crop environment, CruiserMaxx APX delivers the most powerful early-season disease and insect protection available,” said Katie Jaeger, Syngenta Seedcare product lead, in a news release.
While protecting against yield-robbing diseases and insects, CruiserMaxx APX also enables faster, more uniform emergence, stronger plants and roots, and quicker speed-to-canopy.
“With CruiserMaxx APX, best-in-class soybean seed treatment protection is now even better,” Jaeger said. “CruiserMaxx APX combines the proven Vigor Effect and RootingPower that CruiserMaxx Vibrance is known to deliver with supercharged, broad-spectrum, early-season disease and insect protection to give seedlings the strongest possible start from day one.”
CruiserMaxx APX will be available for limited trialing in 2022, with plans for broad availability in 2023, subject to state approvals.